Return to homepagePandemic Pact

Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 4U54CA260563-02

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2025

  • Known Financial Commitments (USD)

    $359,168

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PROFESSOR Ignacio Sanz

  • Research Location

    United States of America

  • Lead Research Institution

    EMORY UNIVERSITY

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidity, Other

  • Occupations of Interest

    Unspecified

Abstract

Abstract COVID-19 infection is greatly heterogenous. Individuals with underlying immune dysregulation, will have abnormal responses to COVID-19, thereby accounting for different short-term outcomes and memory formation. Specifically, emerging evidence indicates poor outcomes in autoimmune and cancer patients. We propose that autoimmune patients and severe COVID-19 infection will share an exacerbated pathological response while cancer patients with disease-associated or treatment-induced immune deficiency, will fail to mount a protective anti-viral response. Here, we shall interrogate the effector B cell response to SARS-CoV-2 to identify determinants of protective and pathogenic responses in HC and autoimmune subjects.